AEON

AEON Biopharma, Inc.

AEON · CIK 1837607 · Annual (10-K) · Last 4 years

Financial Trends

Revenue
20212024
Net Income$42M
20212024
Operating CF−$20M
20212024
Free Cash Flow
20212024

Income Statement

MetricFY 2024FY 2023FY 2022FY 2021
Revenue
Cost of Revenue
Gross Profit
R&D Expense$0.0B$0.0B
SG&A Expense$0.0B$0.0B
Operating Income$0.1B$0.0B$-0.0B$-0.0B
Net Income$0.0B$0.0B$0.0B$0.0B
EPS (Basic)$77.74$0.65
EPS (Diluted)$72.93$0.65

Balance Sheet

MetricFY 2024FY 2023FY 2022FY 2021
Total Assets$0.0B$0.0B$0.3B$0.3B
Current Assets$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.2B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$-0.2B$-0.0B$-0.0B

Cash Flow Statement

MetricFY 2024FY 2023FY 2022FY 2021
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.0B$0.0B$-0.3B
Capital Expenditures$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.3B